Exogene
Exogene applies deep learning to identify tumor-specific T-cell receptors for cancer therapy development. Researchers leverage these AI-discovered receptors to engineer TCR-based treatments with potential curative efficacy.
Founders
Federico Paoletti
CEO
Federico is a computational biologist with deep expertise in mathematical modeling and molecular biophysics. He holds a PhD in Molecular and Computational Oncology from the University of Oxford and has previously worked at the World Health Organization assessing cancer prevention strategies.
Andrea Mambrini
CTO
Andrea is an experienced machine learning scientist. He holds a PhD in Bio-Inspired Computation and has several years of experience building AI. He previously led the ML team at Portent.io (acquired by Yougov) and has worked at the European Space Agency, Honda Research Institute and Vodafone.